INTS INTENSITY THERAPEUTICS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1567264 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-2.6%
TTM EPS YoY90.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-161.8%
ROA-121.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets25.6%
Debt / equity0.00x
Current ratio3.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-29.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $6.79M | $10.50M | $4.79M | $5.13M |
| SG&A expense | $5.19M | $6.09M | $3.53M | $2.42M |
| Operating income | -$11.97M | -$16.59M | -$8.32M | -$7.55M |
| Interest expense | — | $0 | $305,000 | $82,000 |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$11.61M | -$16.27M | -$10.54M | -$7.58M |
| EPS (basic) | -8.56 | -29.24 | -1.38 | -2.22 |
| EPS (diluted) | -8.56 | -29.24 | -1.38 | -2.22 |
| Weighted avg. shares (diluted) | 1.36M | 556,279 | 8.62M | 3.41M |
| Balance sheet | ||||
| Cash & equivalents | $11.92M | $2.59M | $8.56M | $1.31M |
| Current assets | $12.71M | $3.36M | $15.46M | $1.45M |
| Total assets | $14.10M | $4.78M | $17.30M | $1.76M |
| Current liabilities | $2.15M | $1.75M | $3.96M | $6.82M |
| Total liabilities | $2.23M | $1.86M | $4.13M | $6.86M |
| Shareholders' equity | $11.88M | $2.92M | $13.16M | -$15.10M |
| Shares outstanding | 2.52M | 604,915 | 13.71M | 3.41M |
| Cash flow statement | ||||
| Operating cash flow | -$9.23M | -$15.22M | -$7.21M | -$5.48M |
| Investing cash flow | $0 | $6.35M | -$6.02M | $0 |
| Financing cash flow | $18.56M | $2.90M | $20.47M | $2.25M |
| Stock-based compensation | $2.00M | $3.07M | $1.40M | $1.17M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.